SIRT1 has garnered significant attention in the context of gynecologic cancers—especially in ovarian, endometrial, and cervical cancers—due to its multifaceted roles in tumor progression, chemoresistance, and cellular metabolism. Here, SIRT1 is linked to female reproductive organ cancer.